Medtide (SEHK:3880) Stock Drifts As Margin Gains Meet Revenue Reset

Simply Wall St.08-28

Medtide shares have drifted lower over the past week and month, yet the latest half year earnings land with a very different message. The headline is margin power. Net profit margin over the last 12 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2662095636?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-08-28 19:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2662095636","market":"sg","top_or_hot":-1,"title":"Medtide (SEHK:3880) Stock Drifts As Margin Gains Meet Revenue Reset","media":"Simply Wall St.","content":"<div>\n<p>Medtide shares have drifted lower over the past week and month, yet the latest half year earnings land with a very different message. The headline is margin power. Net profit margin over the last 12 ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3880/medtide-shares/news/medtide-sehk3880-stock-drifts-as-margin-gains-meet-revenue-r\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medtide (SEHK:3880) Stock Drifts As Margin Gains Meet Revenue Reset</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedtide (SEHK:3880) Stock Drifts As Margin Gains Meet Revenue Reset\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-28 19:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3880/medtide-shares/news/medtide-sehk3880-stock-drifts-as-margin-gains-meet-revenue-r><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Medtide shares have drifted lower over the past week and month, yet the latest half year earnings land with a very different message. The headline is margin power. Net profit margin over the last 12 ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3880/medtide-shares/news/medtide-sehk3880-stock-drifts-as-margin-gains-meet-revenue-r\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FEBU","symbol_name":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3880/medtide-shares/news/medtide-sehk3880-stock-drifts-as-margin-gains-meet-revenue-r","article_id":"2662095636","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3880/medtide-shares/news/medtide-sehk3880-stock-drifts-as-margin-gains-meet-revenue-r","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2662095636","pubTimestamp":1787916832,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Medtide shares have drifted lower over the past week and month, yet the latest half year earnings land with a very different message. The headline is margin power. Net profit margin over the last 12 months is 30.7%, compared with 22.2% a year earlier, while earnings per share on that same basis sit at 1.19 CNY. The stock closed at HK$21.5 on a trailing P/E of 15.5x, which leaves today’s muted price reaction at odds with the profitability story Medtide just put on the table.\nLove Medtide’s...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","VGFPF":"Vanguard Funds PLC","BK1141":"生命科学工具和服务","03880":"泰德医药","GXDW":"Global X Dorsey Wright Thematic ETF","VOTE":"TCW Transform 500 ETF","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","PMDE":"PGIM S&P 500 Max Buffer ETF - December","JOYT":"JPMorgan Equity and Options Total Return ETF","RGLO":"Global Equity Active ETF"},"translate_title":"Medtide (SEHK:3880) 股价因利润率增长满足收入重置而波动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JOYT":0.69,"VOTE":0.69,"DECU":0.69,"RGLO":0.69,"VGFPF":0.69,"03880":0.9,"PMDE":0.69,"FEBU":0.69,"GXDW":0.69},"content_text":"Medtide shares have drifted lower over the past week and month, yet the latest half year earnings land with a very different message. The headline is margin power. Net profit margin over the last 12 months is 30.7%, compared with 22.2% a year earlier, while earnings per share on that same basis sit at 1.19 CNY. The stock closed at HK$21.5 on a trailing P/E of 15.5x, which leaves today’s muted price reaction at odds with the profitability story Medtide just put on the table. Love Medtide’s strong net margins but want a watchlist of stocks that pair profitability with robust balance sheets and cash flows? Take a look at the list of solid balance sheet and fundamentals stocks (427 results) AdvertisementH1 2026 Earnings Summary  Revenue (H1 2026 vs. H1 2025): 234.518 million CNY vs. 253.767 million CNY (lower period on period) Net Income (Excl. Extra Items, H1 2026 vs. H1 2025): 53.677 million CNY vs. 101.999 million CNY (lower period on period) Basic EPS (H1 2026 vs. H1 2025): 0.38 CNY vs. 0.815992 CNY (lower period on period) Net Profit Margin (TTM vs. Prior Year): 30.7% vs. 22.2% (higher on a trailing 12 month basis)  Prefer clean charts instead of another wall of earnings tables and footnotes? See Medtide’s full financial picture with a visual breakdown of its profitability and margins through the latest company report for Medtide. SEHK:3880 Trailing 12-Month Earnings & Revenue History as at Aug 2026 Medtide margin strength supports cautious optimism For investors focused on Medtide’s GLP‑1 and peptide services story, the margin profile is the clear bright spot. Trailing net profit margin of 30.7%, up from 22.2%, shows the business converting a meaningful share of revenue into earnings even as H1 2026 revenue and EPS run below H1 2025. That combination hints at operational discipline and pricing or mix resilience. It supports a constructive view that Medtide can still earn attractive economics from its platforms while the top line and earnings reset from a stronger prior period. Revenue reset keeps Medtide execution risks in view The bear case finds support in the short term revenue and earnings trend. H1 2026 revenue of 234.518m CNY and net income of 53.677m CNY both sit below H1 2025, with basic EPS nearly halved. That pullback, alongside recent share price weakness over 7, 30 and 90 days, suggests investors are weighing execution and demand risks despite richer trailing margins. For a young GLP‑1 focused services company, the latest numbers keep questions open on growth consistency and sensitivity to project or client swings. Compare Medtide’s stronger trailing margins with the reset in H1 revenue and EPS, then see whether analysts think this earnings profile supports more upside or calls for caution through the consensus price target analysis for Medtide. Stay Ahead With Medtide And Beyond If Medtide’s strong trailing margins and recent share price pullback have your attention, register for free with Simply Wall St and add it to a Watchlist so you can keep an eye on price versus fair value and wait for an entry that fits your plan. Once you are invested, use the Portfolio Command Center to cut through noise and focus on the key updates that matter for your holdings. For a broader view on sentiment and ideas around Medtide and other stocks, tap into the Community to see how different investors are thinking. By spotting hidden catalysts and risks early, you give yourself a better chance to act with confidence and stay ahead of the market. Seeking Alternatives Beyond Medtide? Fresh ideas move fast. Some stocks could be building quiet breakout momentum while others get caught dropping before the crowd reacts. Scan under the radar for now and act with care.  Spot potential breakout leaders with strong financial footing before they start moving by reviewing the curated 613 high quality undiscovered gems that many investors have not noticed yet. Track the energy transition story as it develops and assess companies tied to grid upgrades using a focused set of 38 power grid technology and infrastructure stocks that filters out weaker balance sheets. Explore opportunities in defense, manufacturing and logistics automation by scanning a concentrated group of 37 robotics and automation stocks that are positioned to participate in demand for intelligent machines.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2662095636","isCrawlerRequest":true}